Ennature Biopharma, a global innovator in plant-based nutraceutical solutions, has published new preclinical research in the Journal of Natural Remedies highlighting the mechanism of action behind its flagship turmeric extract, Maxicuma®, a clinically studied ingredient for joint health and mobility.
Maxicuma® is a turmeric extract standardised to 40% curcuminoids, uniquely formulated using Ennature’s proprietary LIMAN™ technology, which is designed to deliver enhanced bioavailability and efficacy at ultra-low doses. Prior clinical trials have already shown its effectiveness in supporting joint comfort and flexibility.
The newly published study, titled "LIMAN™-based Curcumin Formulation (Maxicuma™) Regulates Inflammation and Cartilage Protection Pathways in an Osteoarthritis Model", provides robust mechanistic evidence to support these outcomes. The research reveals that Maxicuma® modulates key inflammatory pathways—notably NF-κB and COX-2—and plays a protective role in cartilage preservation, validating its clinical benefits through molecular data.
“This study bridges the gap between formulation science and functional outcomes,” said Dr. Shuaib Khan, Head of R&D at Ennature Biopharma. “We now have preclinical data showing how Maxicuma® regulates inflammatory markers and protects cartilage at the cellular level—reinforcing its value as a trusted joint health solution.”
With its clean-label certification, scientific substantiation, and performance at low doses, Maxicuma® is ideally positioned for brands developing joint and mobility supplements for active adults, athletes, and healthy aging populations.
To explore formulation opportunities or access the full study, visit: www.maxicuma.com or email ennature@indiaglycols.com
